Naoki Miyamoto

Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation

Yuya Oguro, Naoki Miyamoto, Kengo Okada et al. · Bioorganic & Medicinal Chemistry · 2010 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Element-free Galerkin method for electromagnetic field computations

V. Cingoski, Naoki Miyamoto, Hideo Yamashita · IEEE Transactions on Magnetics · 1998 · 104 citations

Computing, Computational Engineering, Electrical Engineering +11

Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation

Kenichiro Shimokawa, Norihito Shibata, Tomoya Sameshima et al. · ACS Medicinal Chemistry Letters · 2017 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety

Masaki Seto, Naoki Miyamoto, Katsuji Aikawa et al. · Bioorganic & Medicinal Chemistry · 2004 · 102 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10

Development of protein degradation inducers of oncogenic <scp>BCR</scp>‐<scp>ABL</scp> protein by conjugation of <scp>ABL</scp> kinase inhibitors and <scp>IAP</scp> ligands

Norihito Shibata, Naoki Miyamoto, Katsunori Nagai et al. · Cancer Science · 2017 · 99 citations · Full text

Medicine, Molecular Biology, Oncology +15